Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) insider Frazor Titus Edmondson III sold 4,369 shares of the company's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total transaction of $156,803.41. Following the completion of the transaction, the insider now owns 27,217 shares in the company, valued at approximately $976,818.13. The trade was a 13.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Frazor Titus Edmondson III also recently made the following trade(s):
- On Friday, February 28th, Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock. The stock was sold at an average price of $32.98, for a total transaction of $479,661.12.
Zai Lab Trading Up 0.7 %
Shares of NASDAQ ZLAB opened at $36.69 on Friday. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $39.77. The stock's fifty day simple moving average is $32.61 and its two-hundred day simple moving average is $28.69. The stock has a market capitalization of $4.02 billion, a PE ratio of -13.25 and a beta of 1.07.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The company had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. On average, equities analysts predict that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently issued reports on ZLAB shares. JPMorgan Chase & Co. boosted their price target on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th. Bank of America reissued a "neutral" rating and set a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Scotiabank began coverage on Zai Lab in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th.
Read Our Latest Research Report on Zai Lab
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in Zai Lab in the fourth quarter valued at approximately $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab in the 4th quarter worth $31,000. Barclays PLC grew its stake in Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after buying an additional 2,856 shares during the last quarter. US Bancorp DE increased its position in Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock valued at $154,000 after buying an additional 5,534 shares in the last quarter. Finally, Jasper Ridge Partners L.P. purchased a new stake in Zai Lab in the fourth quarter valued at about $210,000. Institutional investors own 41.65% of the company's stock.
About Zai Lab
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
